Venture
Vividion Therapeutics, Inc.
Latest Form D 2021-03-02- CIK 1671687
- State CA
- Biotechnology
- 4 Form D offerings since 2016-04-11
- Total sold
- $241M
- across 4 offerings
- Rounds
- 4
- Form D offerings since 2016-04-11
- Latest round
- $135M
- 2021-03-02 · 021-390895
- Investors
- 27
- on the latest round
Connected
named in its Form D filingsOfferings · since 2016-04-114 Form D offeringsExemptions506(b) · 506(c)People · Item 3Jeffrey Hatfield + 8 moreInvestors · dashboard6 inferred investors
Vividion Therapeutics, Inc.CIK 1671687
Round timeline
amount sold · by first filed2021-03-02 · $135M
- 2016-04-11$3.5M021-261009
- 2017-01-18$20.2M021-278715
- 2019-05-06$82M021-338900
- 2021-03-02$135M021-390895
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($135M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-390895 | First filed2021-03-02 | Latest2021-03-02 | Sought$135M | Sold$135M | Investors27 | Exemptions506(b) |
| 021-338900 | First filed2019-05-06 | Latest2019-05-06 | Sought$82M | Sold$82M | Investors20 | Exemptions506(b) |
| 021-278715 | First filed2017-01-18 | Latest2017-01-18 | Sought$50.5M | Sold$20.2M | Investors8 | Exemptions506(b) |
| 021-261009 | First filed2016-04-11 | Latest2016-04-11 | Sought$4M | Sold$3.5M | Investors1 | Exemptions506(c) |
Who backs Vividion Therapeutics, Inc. — 6 inferred investors — and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2021-03-02
| Name | Relationship |
|---|---|
| Jeffrey Hatfield | RelationshipExecutive Officer, Director |
| Patricia L. Allen | RelationshipExecutive Officer |
| Benjamin Cravatt | RelationshipDirector |
| Kristina Burow | RelationshipDirector |
| John Clarke | RelationshipDirector |
| Richard Heyman | RelationshipDirector |
| Thomas E. Daniel | RelationshipDirector |
| Thomas Woiwode | RelationshipDirector |
| Jakob Loven | RelationshipDirector |
Facts
As its latest Form D states them
- Industry
- Biotechnology
- State
- California (CA)
- Exemptions
- Rule 506(b); Rule 506(c)
- First filed
- 2016-04-11
- Latest filing
- 2021-03-02
Who backs Vividion Therapeutics, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗